Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.|Center for Transfusion and Cellular Therapy, Department of Pathology, Emory University, Atlanta, Georgia.
Robert Sheppard
RS
Nickel
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
Marla
M
Daves
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
Frank
F
Keller
D000293:Adolescent; D019943:Amino Acid Substitution; D002648:Child; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D008297:Male; D020125:Mutation, Missense; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011724:Pyridazines / Q000008:administration & dosage*
D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl